OMG! Kim Kardashian Social Media Post For Morning Sickness Drug Draws FDA Warning
This article was originally published in The Pink Sheet Daily
Executive Summary
Instagram and Facebook post about Duchesnay’s Diclegis lacks risk information, agency notes.
You may also be interested in...
Senators Pressure US FDA To Issue New Guidance On Social Media Drug Promotion
Senators ask the agency to address the “regulatory loophole” permitting telehealth companies to promote prescription drugs without disclosing side effects and question if FDA has enforcement authority over third-party social media influencer promotions.
Drug Promotion: Growth In Digital Marketing Warrants New Oversight Approaches, Experts Say
Panelists at a recent Duke-Margolis meeting cite growing use of native ads and patient influencers, as well as the limited attention given to presentation of risk information, in calling for a re-examination of how pharmaceutical promotion on digital platforms is regulated.
Social Media: Use Of Influencers In Drug Promotion Requires Guardrails, Experts Say
Careful identification and vetting of spokespersons, training on FDA regulations, and development of content that conveys the typical patient experience are keys to successful and compliant influencer campaigns, advertising, legal and regulatory experts told a recent DIA conference.